How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/moderate-to-severe-atopic-dermatitis-in-adults.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Moderate to severe atopic dermatitis in adults — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Moderate to severe atopic dermatitis in adults (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Moderate to severe atopic dermatitis in adults, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Abrocitinib Suspension F1	abrocitinib-suspension-f1	Pfizer	JAK inhibitor	JAK1
Abrocitinib Suspension F6	abrocitinib-suspension-f6	Pfizer	JAK inhibitor	JAK1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 2 drugs in Moderate to severe atopic dermatitis in adults

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Moderate to severe atopic dermatitis in adults:

Cite this brief

Drug Landscape (2026). Moderate to severe atopic dermatitis in adults — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/moderate-to-severe-atopic-dermatitis-in-adults. Accessed 2026-06-10.

Moderate to severe atopic dermatitis in adults full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing